Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | ACACA | Q13085 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18808203 | 0.93 | ELANE (0.41) | ACACBACACAELANEHSD17B1 | |
| SCHEMBL25570389 | 0.92 | CYP2C19 (0.38) | ACACBACACA | |
| SCHEMBL18806020 | 0.89 | ELANE (0.43) | ACACBACACAELANEKMT2AATM | |
| SCHEMBL18806042 | 0.88 | APP (0.40) | ELANEKMT2AATMAKR1C3AKR1C2 | |
| SCHEMBL18806032 | 0.88 | ELANE (0.34) | ACACBACACAELANEKMT2AATM | |
| SCHEMBL18806039 | 0.87 | ELANE (0.41) | ACACBACACAELANEKMT2AATM | |
| SCHEMBL18806022 | 0.84 | APP (0.41) | ELANEKMT2AAKR1C3AKR1C2LMNA | |
| SCHEMBL18806043 | 0.84 | APP (0.44) | ELANEKMT2AAKR1C3AKR1C2LMNA | |
| SCHEMBL940907 | 0.84 | ELANE (0.48) | ACACBACACAELANEKMT2AATM | |
| SCHEMBL18806023 | 0.83 | AKR1C3 (0.39) | ELANEKMT2AATMAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400561-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024133363-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024132893-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024126567-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240067879-A1 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| US-20240067879-A1 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| EP-4306614-A1 | LIQUID-CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306615-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023208801-A1 | LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209049-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023203043-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| US-20230183571-A1 | LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183571-A1 | LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| WO-2023066953-A1 | LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023052283-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-04-06 | — | — | WO | disclosed |
| US-11312909-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2022-04-26 | — | — | US | disclosed |
| EP-3162875-B1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2018-05-23 | — | — | EP | disclosed |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | GMBH, MERCK PATENT (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | GMBH, MERCK PATENT (DE) | 2017-05-04 | — | — | US | disclosed |
| EP-3162875-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | Merck Patent GmbH (DE) | 2017-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312909-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | VCL, LCP1, MAP1LC3C | ACACB 3772/4885ACACA 3438/4885ELANE 766/4885 |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, LCP1, MAP1LC3C | ACACB 3682/4885ACACA 3237/4885ELANE 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.